Tumor growth control with IDO-silencing Salmonellareply

Cancer Research

Volumn 73, Issue 14, 2013, Pages 4592-4593

  Manuel, Edwin R ^a   Blazar, Bruce R ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; INDOLEAMINE 2,3 DIOXYGENASE; SHORT HAIRPIN RNA;

BACTERIAL COLONIZATION; CANCER INHIBITION; HUMAN; LETTER; METASTATIC MELANOMA; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TUMOR REGRESSION;

ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; RNA, SMALL INTERFERING; SALMONELLA TYPHIMURIUM; TRANSFORMATION, BACTERIAL;

EID: 84880879679     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1274     Document Type: Letter

References (10)

1. Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JD, Blazar BR, et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res 2012;72:6447-56.
2. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, et al. Tumortargeting bacterial therapy with amino acid auxotrophs of GFPexpressing Salmonella typhimurium. Proc Natl Acad Sci U S A 2005;102:755-60.
3. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000;181:1996-2002.
4. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
5. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737-44.
6. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 2011;71: 4183-91.
7. Ryan RM, Green J, Williams PJ, Tazzyman S, Hunt S, Harmey JH, et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther. 2009;16:329-39.
8. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother 2009;58:769-75.
9. Peng K, Monack DM. Indoleamine 2, 3-dioxygenase 1 is a lungspecific innate immune defense mechanism that inhibits growth of Francisella tularensis tryptophan auxotrophs. Infect Immun 2010; 78:2723-33.
10. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2, 3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989;45:535-41.